OA  /  E-mail  /    中文版         

Search

1

 China National Scientific Instruments
Your location:
Homepage
/
/
Company
05-28

Sinopharm held a video conference on office line work in 2022

In order to further strengthen the office line management of subsidiaries, deploy relevant key tasks, and ensure that various management requirements are in place, on April 20, Sinopharm held a video conference on office line work in 2022. A total of 554 people attended the meeting, including office directors and related office staff of the third-level subsidiaries. Du Jiang, deputy general manager of Sinopharm Instruments, attended the meeting and delivered a speech. The meeting was presided over by Yu Yu, deputy director of the general manager's office (presiding over the work). Du Jiang affirmed the hard work of the company's office line staff at all levels in the past year. He briefly reviewed the achievements of Sinopharm Instruments in 2021, and put forward three requirements for the office line: first, to think about big things, to plan Big things, big things. In 2021, the whole system of Sinopharm equipment has undergone the political inspection of the SASAC Party Committee. Companies at all levels have sorted out and formulated a list of issues and rectification resolutions, which involve important matters in all aspects of the company. Office directors should pay close attention to them and actively promote them in accordance with the rectification requirements. At the forefront of work, be a staff assistant to a good leader. The second is to focus on the key tasks of this year, make overall arrangements, and improve efficiency. In 2022, the office line must continue to promote the standardization and standardization of daily work. In addition, it must actively cooperate with the audit of the National Audit Office and the 7 internal control inspections carried out by the State-owned Assets Supervision and Administration Commission. Office directors must plan ahead, improve the mechanism, and develop creatively. Work. The third is to talk about study, talk about politics, talk about righteousness, and strengthen team building. In recent years, the company has developed rapidly, and management requirements and work procedures have been updated frequently. In the face of new documents and new requirements from superiors, the director of the office must not only communicate correctly, but also earnestly study and understand the contents of the documents, and strive to build an efficient office team. Yu Yu reviewed the key work of the office line in 2021, and deployed the key work in 2022 from the seven aspects of office meeting, system, brand, seal, confidentiality, official documents, and archives, focusing on specific requirements for confidentiality management. Huang Haiying, director of the administration department, explained the company's relevant standards and red line requirements from the aspects of official vehicles, office space, business hospitality, fixed assets, and business travel services. In order to continuously improve the basic management level of subsidiary offices and let subsidiaries understand the latest management requirements of superiors, at the meeting, Wu Lin of the Risk and Operation Management Department of the Headquarters, Song Jingjing, Li Zhuoran, Yuan Yong, Zhang Mian of the General Manager Office, and Wang Xin of the Public Affairs Department , Fan Xiao, and Shu Changning of the Logistics Management Department, respectively, from the work requirements of system "abolition and reformation", brand management and VI use, office meeting process, confidentiality work priorities, lean file management and association joining, cooperation agreement signing, public opinion management, Publicity and training were carried out for subsidiaries in terms of news publicity and engineering construction management. The content of this meeting integrates the management functions of the subsidiary's office line, and provides targeted explanations around the difficulties and problems encountered in daily work, which will surely further strengthen the subsidiary's basic management level and effectively promote the company's health. develop.
05-28

Sinopharm Instruments and Dongfang Biotech signed a strategic cooperation agreement

On March 25, 2022, China Medical Devices Co., Ltd. (hereinafter referred to as "Sinopharm Instrument") and Zhejiang Dongfang Gene Biological Products Co., Ltd. (hereinafter referred to as "Dongfang Bio") signed a strategic cooperation agreement in the form of an online contract. Zhang Wei, deputy general manager of Sinopharm Instruments, and Xu Faying, deputy general manager of Oriental Biological Sales, signed the contract on behalf of both parties. He Tao, President of Zhejiang Medical Device Industry Association, Li Jianfei, Assistant General Manager of Sinopharm, Hu Zhenyu, Deputy General Manager of the Western Division, Hu Pan, Director of Marketing, Yan Jipeng, Deputy Director, Zhao Hui, Executive Deputy General Manager and Deputy General Manager of Sinopharm Zhejiang Company Zhao Liang and Zhan Yao, Director of the General Manager's Office of Oriental Biology, attended the ceremony and witnessed the signing ceremony. Oriental Bio was established in 2005 and listed on the Shanghai Stock Exchange's Science and Technology Innovation Board in 2020. It is an enterprise specializing in the production, sales and research of IVD in vitro diagnostic products. Its business fields cover molecular diagnostic platforms, POCT rapid diagnostic platforms, and liquid biochip platforms. On March 15, 2022, it became the first medical device enterprise in Zhejiang Province to obtain the registration certificate for the domestic novel coronavirus antigen detection kit. Deputy General Manager Zhang Wei pointed out in the signing speech that with the signing of this strategic cooperation agreement, Sinopharm will give full play to the advantages of integrated marketing, and rely on the national network layout and logistics and information resources to deepen cooperation with Orient Bio in various aspects. Cooperation. At the same time, Sinopharm Instruments, as a national strategic reserve enterprise for medical devices, will jointly support the domestic new crown epidemic prevention and control needs through cooperation with Orient Bio in the new crown antigen detection kit. Deputy General Manager Xu Faying also expressed his willingness to share resources with Sinopharm and form a joint development force. President He Tao congratulated the two sides on the strategic cooperation and hoped that the two sides would make new contributions during the special period of epidemic prevention and control. In the future, Sinopharm Instruments and Orient Bio will build a nationwide professional supply chain channel to provide a full range of high-quality services for downstream distributors, terminal hospitals and more people.
03-07

Sinopharm China Bio-Omicron Variant Novel Coronavirus Inactivated Vaccine Obtained Clinical Approval from the State Food and Drug Administration

Sinopharm Sinopharm Group China Biotech introduced the Omicron variant strain from the University of Hong Kong for the first time on the basis of the prototype new crown inactivated vaccine and the completion of the development of beta and delta variant inactivated vaccines in the early stage, December 2021 On the 9th, the research and development of the Austrian strain inactivated vaccine was quickly launched. According to the guiding principles and research and development strategies of the improved new crown vaccine of the State Food and Drug Administration, Sinopharm Group China Biotechnology has completed the screening, passage and expansion of the Austrian strain by using the newly built P3 high-level biosafety laboratory, and established a three-level virus. The seed bank has completed process verification, preparation of multiple batches of large-scale products, quality standard research, safety evaluation in animals and immunogenicity research. titer of neutralizing antibodies. On March 3, 2022, the Beijing Institute of Biology of Sinopharm, Wuhan Institute of Biology and Hong Kong research institutions confirmed the clinical plan and related details. The clinical application materials were submitted to the Hong Kong Department of Health on the 1st, the ethics approval was obtained on April 12th, and the clinical research approval was obtained on April 13th, becoming the world's first inactivated vaccine of Chronomicron strains approved for clinical use. At the same time of Sinopharm, Sinopharm Group Sino Bio began to submit domestic clinical application materials to the Drug Evaluation Center of the State Food and Drug Administration on a rolling basis from January 26 to start the technical review. Sinopharm On April 26, Sinopharm China Bio-Beijing Biological Products Research Institute's Omicron variant new coronavirus inactivated vaccine obtained the clinical approval issued by the State Food and Drug Administration of China. Sinopharm Group China Biotechnology will use a randomized, double-blind, cohort study to conduct a sequential immunization clinical study in people aged 18 and over who have completed 2 or 3 doses of the new crown vaccine to evaluate the efficacy of the new crown virus of the Omicron variant. Safety and immunogenicity of live vaccines. Sinopharm shoulders the political and social responsibilities of a central enterprise. Sinopharm Group China Bio has independently developed 4 new crown diagnostic reagents, 4 new crown specific treatment drugs and successfully developed three technical routes in the three fields of "diagnosable, curable and preventable". The four new crown vaccines have given full play to the role of the national team, main force and pillar of the pharmaceutical industry, created a strategic scientific and technological force to maintain national biosecurity, and promoted Chinese vaccines and therapeutic drugs to benefit the Chinese people and the world.
03-07

Sinopharm held a video conference on office line work in 2022

In order to further strengthen the office line management of subsidiaries, deploy relevant key tasks, and ensure that various management requirements are in place, on April 20, Sinopharm held a video conference on office line work in 2022. A total of 554 people attended the meeting, including office directors and related office staff of the third-level subsidiaries. Du Jiang, deputy general manager of Sinopharm Instruments, attended the meeting and delivered a speech. The meeting was presided over by Yu Yu, deputy director of the general manager's office (presiding over the work). Du Jiang affirmed the hard work of the company's office line staff at all levels in the past year. He briefly reviewed the achievements of Sinopharm Instruments in 2021, and put forward three requirements for the office line: first, to think about big things, to plan Big things, big things. In 2021, the whole system of Sinopharm equipment has undergone the political inspection of the SASAC Party Committee. Companies at all levels have sorted out and formulated a list of issues and rectification resolutions, which involve important matters in all aspects of the company. Office directors should pay close attention to them and actively promote them in accordance with the rectification requirements. At the forefront of work, be a staff assistant to a good leader. The second is to focus on the key tasks of this year, make overall arrangements, and improve efficiency. In 2022, the office line must continue to promote the standardization and standardization of daily work. In addition, it must actively cooperate with the audit of the National Audit Office and the 7 internal control inspections carried out by the State-owned Assets Supervision and Administration Commission. Office directors must plan ahead, improve the mechanism, and develop creatively. Work. The third is to talk about study, talk about politics, talk about righteousness, and strengthen team building. In recent years, the company has developed rapidly, and management requirements and work procedures have been updated frequently. In the face of new documents and new requirements from superiors, the director of the office must not only communicate correctly, but also earnestly study and understand the contents of the documents, and strive to build an efficient office team. Yu Yu reviewed the key work of the office line in 2021, and deployed the key work in 2022 from the seven aspects of office meeting, system, brand, seal, confidentiality, official documents, and archives, focusing on specific requirements for confidentiality management. Huang Haiying, director of the administration department, explained the company's relevant standards and red line requirements from the aspects of official vehicles, office space, business hospitality, fixed assets, and business travel services. In order to continuously improve the basic management level of subsidiary offices and let subsidiaries understand the latest management requirements of superiors, at the meeting, Wu Lin of the Risk and Operation Management Department of the Headquarters, Song Jingjing, Li Zhuoran, Yuan Yong, Zhang Mian of the General Manager Office, and Wang Xin of the Public Affairs Department , Fan Xiao, and Shu Changning of the Logistics Management Department, respectively, from the work requirements of system "abolition and reformation", brand management and VI use, office meeting process, confidentiality work priorities, lean file management and association joining, cooperation agreement signing, public opinion management, Publicity and training were carried out for subsidiaries in terms of news publicity and engineering construction management. The content of this meeting integrates the management functions of the subsidiary's office line, and provides targeted explanations around the difficulties and problems encountered in daily work, which will surely further strengthen the subsidiary's basic management level and effectively promote the company's health. develop.
03-07

The Disciplinary Committee of Sinopharm Instruments Launches Epidemic Prevention and Control Supervision and Inspection

In order to conscientiously implement the spirit and requirements of Sinopharm Group, Sinopharm Holding and Sinopharm Device Party Committee on strengthening epidemic prevention and control work, recently, the company's Disciplinary Committee has urged companies at all levels to deeply understand the importance and urgency of epidemic prevention and control work, and always adhere to "" The concept of "people first, life first" will further consolidate the responsibility for prevention and control, and coordinate the implementation of various tasks such as epidemic prevention and control and enterprise development. In view of the current situation of the new crown epidemic with many points, wide areas and frequent occurrences, as well as the characteristics of strong infectivity, fast transmission and strong concealment of the Omicron variant strain, in the face of the increasingly severe and complicated situation of epidemic prevention and control, Sinopharm Instruments Co., Ltd. The Commission for Discipline Inspection requires enterprise party organizations and disciplinary committees at all levels to fully implement the main responsibilities and supervision responsibilities of epidemic prevention and control, and ensure that various prevention and control measures are implemented. Recently, led by the company's Disciplinary Committee, the company's Deputy Secretary of the Party Committee and Secretary of the Disciplinary Committee Guo Yong led the team. The company's Disciplinary Committee, the Administration Department and the Disciplinary Inspection Office jointly formed an inspection team to supervise the epidemic prevention and control work of 8 units including Sinopharm's Beijing subsidiary. examine. During the inspection, Guo Yong affirmed the subsidiary's epidemic prevention and control work, and put forward opinions and suggestions on the deficiencies in key areas and key links. He emphasized: First, it is necessary to improve the political position. In the face of the current severe situation of epidemic prevention and control, companies at all levels must conscientiously unify their thoughts and actions into the spirit of General Secretary Xi Jinping's important instructions on epidemic prevention and control, and further improve their efforts to handle the epidemic. Political awareness, ideological awareness and action awareness of prevention and control work, and strict and swift implementation of various prevention and control measures. The second is to strictly guard against the epidemic. The epidemic is an order, and prevention and control is a responsibility. Party organizations at all levels of the company must further implement the speech of Comrade Liu Jingzhen, secretary of the party committee and chairman of Sinopharm Group, on March 16. Regarding deployment arrangements, various prevention and control measures should be implemented in detail through measures such as strengthening work coordination, strengthening personnel management and control, and strengthening site management. Third, enterprises at all levels should strengthen joint prevention and control with their territories, and earnestly implement various epidemic prevention requirements of the territorial governments. Enterprises affiliated to Shanghai, Jilin and other key areas of current epidemic prevention and control must obey the local unified command, coordinate and dispatch, and actively cooperate with the local government in personnel management and control, close isolation, nucleic acid testing, and on-duty work. The fourth is to continue to ensure the supply of medical materials, strictly control quality, and do a good job in the distribution of prevention and control materials to key areas and hospital customers in an orderly and efficient manner, reflecting the responsibility of central enterprises. Fifth, all enterprises in Beijing should conscientiously implement the requirements of the capital's joint prevention and control mechanism, and do a solid job in epidemic prevention and control. Sixth, the medical management and medical-industrial sectors should conscientiously do a good job in site disinfection, strengthen the personal protection of project personnel and medical staff stationed in hospitals, and resolutely prevent nosocomial infections and other incidents.

Contact  

Business cmiczkq@sinopharm.com

Hotline:86-27-84888155 

 

Address:No.666, Gaoxin Avenue, Wuhan East Lake High-Tech Development Zone, Wuhan City,Hubei Province, China Copyright © csimcwh.com All Rights Reserved

   ICP:13017258-1  Power by www.300.cn     SEO

Address:No.666, Gaoxin Avenue, Wuhan East Lake High-Tech Development Zone, Wuhan City,Hubei Province

China Copyright © csimcwh.com All Rights Reserved

 ICP:13017258-1  Power by www.300.cn  

 China National Scientific Instruments